Cystic fibrosis almost always requires a child to inherit a faulty copy of the CFTR gene from each parent, meaning both parents are typically carriers. In rare but well-documented situations, though, CF can appear even when only one parent is a known carrier. The explanations range from mutations hiding from standard screening panels to genuinely new mutations that arise spontaneously, and each scenario carries different implications for the family.
How CF Inheritance Normally Works
CF follows an autosomal recessive inheritance pattern. You have two copies of the CFTR gene, one from each parent. If both copies carry a disease-causing mutation, you develop CF. If only one copy is mutated, you’re a carrier with no symptoms. When both parents are carriers, each pregnancy has a one-in-four chance of producing a child with CF. That much is straightforward. The question gets interesting when genetic testing identifies a mutation in only one parent but the child still has the disease.
When this happens, the reflexive assumption is often that something impossible occurred. In reality, several biological and practical explanations exist, and by far the most common one is not exotic at all: the second parent does carry a CFTR mutation, but the screening test simply didn’t detect it.
The Most Likely Explanation: A Mutation the Test Missed
Standard carrier screening panels do not look at every possible CFTR mutation. They typically test for a curated list of the most common ones. The most widely used panel in the United States checks for 23 mutations. That catches the majority of carriers in populations of European descent, but it leaves gaps. In a study of over 13,000 couples, about 31% of at-risk carrier couples would have been missed by a 23-mutation panel alone, potentially resulting in four to five additional CF cases that screening failed to flag.1Nature. Sequencing as a first-line methodology for cystic fibrosis carrier screening That is not a trivial gap.
The issue is especially pronounced in people of non-European backgrounds. Roughly 2,000 different sequence changes have been documented in the CFTR gene, and the mutations that show up most frequently vary by ethnicity and geographic origin.2PLoS ONE. Applicability and Efficiency of NGS in Routine Diagnosis: In-Depth Performance Analysis of a Complete Workflow for CFTR Mutation Analysis A panel designed around Northern European populations will catch fewer mutations in people of African, Asian, Latin American, or Middle Eastern descent. So when a parent of a child with CF tests “negative” on a standard screen, the first thing clinicians investigate is whether a less common mutation was simply not on the panel.
Beyond point mutations, large structural rearrangements in the CFTR gene, like big deletions or duplications spanning entire stretches of DNA, can also cause CF but are rarely caught by routine screening methods.3PubMed Central. Identification of a novel large deletion and other copy number variations in the CFTR gene in patients with Cystic Fibrosis from a multiethnic population These structural changes need specialized techniques to detect, and many labs don’t include them in first-line testing. In ethnically diverse populations, a meaningful fraction of disease-causing changes fall into this category.
What Residual Risk Means After a Negative Test
A negative carrier screening result does not mean the risk is zero. Geneticists call the leftover probability “residual risk,” and it depends on two things: how common carriers are in your population group and how many of those carriers the test can actually identify.4PubMed. A Transparent Approach to Calculate Detection Rate and Residual Risk for Carrier Screening For someone of Northern European ancestry, the residual risk after a negative 23-mutation panel is low but not negligible. For someone from a population where carrier frequency estimates are less precise or unavailable, residual risk calculations become unreliable.5PubMed Central. Challenges in providing residual risks in carrier testing
This is why genetic counselors emphasize that a negative result “reduces” risk rather than “eliminates” it. If you’re told one parent is a carrier and the other tested negative, the chance of having a child with CF drops dramatically compared to two confirmed carriers, but it doesn’t reach zero. The remaining risk is small in most circumstances, yet it’s the very scenario this article addresses: rare, but real.
De Novo Mutations: When a New Mutation Appears for the First Time
In extremely rare cases, a CFTR mutation isn’t inherited from either parent. Instead, it arises spontaneously in the egg or sperm cell that formed the child. These are called de novo mutations. One documented case involved a child in Poland who had severe CF caused by a large deletion spanning several sections of the CFTR gene. One parent carried a known mutation, and the deletion was confirmed to be brand-new, not present in either parent’s DNA.6The Journal of Pediatrics. Novel de Novo Large Deletion in Cystic Fibrosis Transconductor Regulator Gene Results in a Severe Cystic Fibrosis Phenotype A more recent case described what appears to be a paternal germline mutation in an Iranian patient, where the child carried two different CFTR variants but only the mother’s mutation was inherited in the traditional sense.7PubMed Central. Identification and in silico structural analysis for the first de novo mutation in the cystic fibrosis transmembrane conductance regulator protein in Iran: case report and developmental insight using microsatellite markers
De novo CFTR mutations are vanishingly uncommon. CF is unusual in this respect, because in many other genetic conditions, new mutations account for a sizable share of cases. The CFTR gene happens to be large, but its mutation rate for spontaneous new changes is low. Still, when all other explanations have been ruled out, a de novo event is a recognized possibility. The practical consequence for the family is significant: if the mutation truly arose for the first time, the chance of it happening again in a sibling is essentially the same as the general population risk, not the one-in-four recurrence risk that applies when both parents are carriers.
Uniparental Disomy: Two Copies from One Parent
Another rare mechanism involves the child inheriting both copies of chromosome 7 (where the CFTR gene sits) from the same parent instead of one from each. This is called uniparental disomy. If the carrier parent contributes both copies and both happen to carry the mutation, the child ends up with two faulty copies despite the other parent contributing nothing abnormal to that chromosome.
The earliest reported case involved a four-year-old with CF and unusually short stature. Genetic analysis across the full length of chromosome 7 showed no paternal contribution at any informative location tested. The child had inherited both copies of chromosome 7 from the mother, who was a CF carrier.8PubMed Central. Isodisomy of chromosome 7 in a patient with cystic fibrosis: could uniparental disomy be common in humans? The short stature in that case was likely a consequence of uniparental disomy as well, since chromosome 7 contains imprinted genes that affect growth.
Uniparental disomy is not unique to CF. It has been documented across many chromosomes and conditions. But it remains genuinely rare, and it’s the kind of explanation that emerges only after thorough genetic workup when the expected two-carrier pattern doesn’t hold.
Misattributed Paternity
This is the explanation nobody wants to discuss, but geneticists encounter it regularly. If the biological father is not who the family believes, then the tested “father” may indeed not be a carrier, yet the biological father could be. Studies of carrier screening uptake note that misattributed paternity occurs in roughly 10% of cases where carrier testing is pursued during pregnancy.9PubMed. Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions This statistic reflects misattributed paternity broadly across prenatal carrier testing, not just CF, but it illustrates how common the issue is.
When a child has CF and one parent tests negative, genetic counselors are trained to consider this possibility with sensitivity. It’s not the first explanation they raise, but it’s a practical reality that changes the genetic math entirely. In these situations, the child does have two carrier parents; it’s just that one of them hasn’t been tested.
When It Looks Like CF but Isn’t Quite
Some children present with symptoms that closely resemble CF but are caused by mutations in genes other than CFTR. One area of research has focused on the epithelial sodium channel, or ENaC, which works alongside the CFTR protein to regulate salt and water movement in the lungs and other tissues. Mutations in ENaC subunit genes have been found at significantly elevated rates in patients with CF-like disease who don’t have two classic CFTR mutations. In one study, rare ENaC variants were present in about 30% of patients with CF-like symptoms, compared to 9% of healthy controls.10PubMed. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease
This doesn’t mean these patients have CF in the strict genetic sense. But from a family’s perspective, the distinction can feel academic when their child has chronic lung problems, difficulty gaining weight, and elevated sweat chloride levels. These CF-like presentations sometimes surface when one parent is a CFTR carrier and the child inherits that single mutation alongside an ENaC variant that amplifies its effect. The interplay between CFTR and ENaC channels in airway tissue means that disrupting one can magnify the consequences of partial disruption in the other.
Modifier Genes and Why Two People with the Same Mutations Can Look Very Different
Even among people with confirmed CF who carry two clear CFTR mutations, disease severity varies enormously. Part of this comes down to which specific CFTR mutations they have, but part of it comes from other genes scattered across the genome. A systematic review identified over 80 modifier genes associated with CF outcomes, spanning inflammation, immune response, gut health, and respiratory function.11PubMed Central. Impact of Gene Modifiers on Cystic Fibrosis Phenotypic Profiles: A Systematic Review A large whole-genome study of nearly 8,000 CF patients identified specific regions on chromosomes 5 and 11 that significantly influenced lung disease severity, with some genetic variants at those locations pushing disease in opposite directions depending on which combination a person carried.12American Journal of Respiratory and Critical Care Medicine. Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 Patients
These modifiers don’t cause CF on their own, and they don’t explain how CF can arise from a single carrier parent. But they’re relevant to this discussion because they help explain why some borderline cases are confusing. A person with one classic CFTR mutation and one very mild mutation might have disease so subtle it’s barely noticeable, while another person with the same pair might have significant symptoms depending on their modifier gene background. This variability can lead to delayed diagnosis and confusion about the inheritance pattern.
What Happens Next: Expanded Testing and Treatment Eligibility
When CF is suspected but only one parent is a confirmed carrier, the clinical path usually involves expanded genetic testing. Next-generation sequencing of the entire CFTR coding region, including deep intronic areas and copy number analysis, can uncover mutations that standard panels miss.2PLoS ONE. Applicability and Efficiency of NGS in Routine Diagnosis: In-Depth Performance Analysis of a Complete Workflow for CFTR Mutation Analysis Sweat chloride testing remains a cornerstone of CF diagnosis regardless of the genetic findings, providing a functional measure of CFTR activity that doesn’t depend on knowing the exact mutations involved.
Identifying the specific mutations matters beyond diagnosis. CFTR modulator therapies, the drugs that have transformed CF treatment in recent years, work only on certain types of mutations. A study testing the response of 655 different CFTR variants to the triple-combination therapy elexacaftor/tezacaftor/ivacaftor found that about 150 variants not currently approved for treatment showed meaningful improvement in chloride transport function, and another 140 variants with partial baseline function also responded well.13PubMed Central. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis For patients whose mutations were only identified through expanded testing, these data can open doors to treatment options that might otherwise have been overlooked.
Carrier Screening in Reproductive Contexts
The question of carrier status becomes especially charged during family planning and when using donor gametes. When egg or sperm donors are involved, screening protocols typically exclude carriers. But some programs have allowed CF carriers to remain in donor pools when the recipient’s partner tests negative.14PubMed. Inclusion of heterozygotes for cystic fibrosis in the egg donor pool The logic is that with one confirmed carrier and one confirmed non-carrier, the risk of CF in the offspring is extremely low. That reasoning holds well in most cases, but as this article has laid out, “non-carrier” on a standard screen doesn’t mean zero residual risk.
Paternal carrier testing during pregnancy is also underutilized. Fewer than half of partners complete follow-up testing after a pregnant person is found to be a carrier.9PubMed. Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions This means many pregnancies proceed with incomplete risk assessment. When the partner’s status is unknown, the question in this article’s title becomes more than hypothetical: it reflects a real gap in how screening plays out in practice.
Global Variation in CFTR Mutations
The landscape of CFTR mutations differs substantially across populations. The most common CF-causing mutation worldwide, a deletion called F508del, accounts for roughly 70% of CF chromosomes in Northern European populations but is far less dominant elsewhere. A study of 15 Chinese children with CFTR-related disease found a different spectrum of mutations, with several variants that would not appear on Western-centric screening panels.15PubMed Central. Clinical and genetic characteristics of diseases caused by CFTR gene mutations in 15 Chinese children: a retrospective analysis In populations where CF is considered rare, diagnostic delays are common because clinicians aren’t looking for it, and when they do test, the panels they use may not include the relevant regional variants.
This population-level diversity in mutations feeds directly back into the “one carrier parent” scenario. In a family from an underrepresented population, the chance that a second parent’s mutation is simply absent from the screening panel is higher than average. Expanded sequencing resolves most of these cases, but access to comprehensive testing varies widely by country and healthcare system. For families in this situation, pushing for full CFTR gene sequencing rather than accepting a panel-based “negative” result at face value is often the most productive next step.